All In Biotech

Drug Trial Radar · NCT06813924

A Research Study of the Effect of Etavopivat on Other Drugs in Healthy Participants

An Open-Label, Fixed-Sequence Study to Evaluate the Effect of Etavopivat on the Single-Dose Pharmacokinetics of Midazolam, Digoxin, Rosuvastatin, Pitavastatin, and Metformin in Healthy Adult Participants

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

37

Actual

Start

Feb 6, 2025

Primary completion

May 27, 2025

Study completion May 27, 2025

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Feb 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The study aims to test if a new medicine called etavopivat potentially affects other medicines in healthy participants. The purpose of the study is to investigate whether the use of etavopivat affects the breakdown and metabolism of commonly used medicines in the body. During the study, participants will receive etavopivat and five different medicines that are already approved and available on the market, and which can be prescribed by doctors. These marketed medicines are called substrate drugs and they are: digoxin, pitavastatin, metformin, midazolam, and rosuvastatin. During a period of the study, participants will take 2 tablets of etavopivat daily for 10 consecutive days. The study will last for about 34 to 64 days.

Conditions

  • Healthy Volunteers Sickle Cell Disease, Thalassemia

Interventions

  • EtavopivatDrug

    Participants will receive a daily dose of etavopivat orally.

  • DigoxinDrug

    Participants will receive a single dose of digoxin orally.

  • PitavastatinDrug

    Participants will receive a single dose of pitavastatin orally.

  • MetforminDrug

    Participants will receive a single dose of metformin orally.

  • MidazolamDrug

    Participants will receive a single dose of midazolam orally.

  • RosuvastatinDrug

    Participants will receive a single dose of rosuvastatin orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cmax, digoxin, SD: Maximum observed digoxin plasma concentration with and without etavopivat at steady stateTime frame: Day 1 and day 3 after digoxin administration
  2. AUC0-inf, digoxin, SD: Area under the digoxin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady stateTime frame: Day 1 and day 3 after digoxin administration
  3. Cmax, rosuvastatin, SD: Maximum observed rosuvastatin plasma concentration with and without etavopivat at steady stateTime frame: Day 1 after rosuvastatin administration
  4. AUC0-inf, rosuvastatin, SD: Area under the rosuvastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady stateTime frame: Day 1 after rosuvastatin administration
  5. Cmax, midazolam, SD: Maximum observed midazolam plasma concentration without etavopivat, with a single dose of etavopivat, and with etavopivat at steady stateTime frame: Day 1 after midazolam administration
  6. AUC0-inf, midazolam, SD: Area under the midazolam plasma concentration-time curve from 0 hours and extrapolated to infinity without etavopivat, with a single dose of etavopivat, and with etavopivat at steady stateTime frame: Day 1 after midazolam administration
  7. Cmax, pitavastatin, SD: Maximum observed pitavastatin plasma concentration with and without etavopivat at steady stateTime frame: Day 1 and day 3 after pitavastatin administration
  8. AUC0-inf, pitavastatin, SD: Area under the pitavastatin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady stateTime frame: Day 1 and day 3 after pitavastatin administration
  9. Cmax, metformin, SD: Maximum observed metformin plasma concentration with and without etavopivat at steady stateTime frame: Day 1 and day 3 after metformin administration
  10. AUC0-inf, metformin, SD: Area under the metformin plasma concentration-time curve from 0 hours and extrapolated to infinity with and without etavopivat at steady stateTime frame: Day 1 and day 3 after metformin administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON-Salt Lake City

    Salt Lake City, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.